The costs and benefits were not reported, but the authors stated that atomoxetine led to higher costs and more QALYs gained than all the comparators.
The incremental cost per QALY gained with atomoxetine versus immediate-release methylphenidate was £15,224 in stimulant-naive patients, and £15,878 in stimulant-averse patients, who were patients whose parents wanted them to change from immediate-release methylphenidate to atomoxetine.
The incremental cost per QALY gained with atomoxetine over extended-release methylphenidate was £13,241 in stimulant-naive patients and £14,169 in stimulant-averse patients.
The incremental cost per QALY gained with atomoxetine over dexamphetamine was £14,945 in stimulant-failed patients, who had failed on either immediate- or extended-release methylphenidate.
In comparison with no treatment, the incremental cost per QALY gained with atomoxetine was £11,523 in stimulant-contraindicated, drug-naive patients and £12,370 in stimulant-contraindicated patients, who had been previously exposed to stimulants.
The authors stated that the results were robust in all scenarios considered in the sensitivity analyses, but the data were not reported.